When the S&P 500 slipped by over 1% on general profit-taking, Merck shares bucked the trend with a 1.35% gain. Trading volume was roughly 20% above Merck’s 30-day average, driven by two analyst upgrades that raised 12-month revenue forecasts by an average of 4%. Investors cited stronger-than-expected quarterly guidance for Keytruda and improved visibility on the non-oncology pipeline as primary catalysts for the outperformance.

Over the past six months Merck stock has climbed 41%, reflecting a modest 5% year-over-year revenue increase to $15.8 billion in its latest quarter and a more pronounced 18% jump in net income to $4.2 billion. Gross margins expanded by 220 basis points thanks to manufacturing efficiencies and favorable product mix, while free cash flow reached $6.1 billion, up 12% year-on-year. These metrics have underpinned growing investor confidence and upward revisions to full-year EPS estimates.

With Keytruda now well-established, Merck is pivoting investor attention to recently launched non-oncology assets Capvaxive and Winrevair. Management forecasts these products will contribute 2–3% of total revenue in Q4. The Animal Health division, which delivered an 8% sales increase in the last quarter, is expected to maintain mid-single-digit growth driven by expanded distribution in Europe. Analysts are also watching late-stage data readouts from two Phase 3 immunology studies due in Q1, which could provide additional upside risk to guidance.